| scholarly article | Q13442814 |
| P2093 | author name string | Ching-Po Lin | |
| Mu-N Liu | |||
| Chi-Ieong Lau | |||
| P2860 | cites work | Tau Filaments and the Development of Positron Emission Tomography Tracers. | Q50350781 |
| Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts | Q50355391 | ||
| Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia | Q50994570 | ||
| Memantine in behavioral variant frontotemporal dementia: negative results. | Q51824504 | ||
| Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. | Q51973117 | ||
| NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. | Q52589491 | ||
| An Overview on the Clinical Development of Tau-Based Therapeutics. | Q52594209 | ||
| Frontotemporal dementia. | Q53268278 | ||
| Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. | Q53288614 | ||
| Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology. | Q55339752 | ||
| Genetics of dementia | Q56069696 | ||
| Phenylindanes in Brewed Coffee Inhibit Amyloid-Beta and Tau Aggregation | Q58122620 | ||
| A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease | Q58202813 | ||
| Repurposing Proteostasis-Modifying Drugs to Prevent or Treat Age-Related Dementia: A Systematic Review | Q58697971 | ||
| Biomarkers for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Associated With Hexanucleotide Expansion Mutations in | Q60046457 | ||
| CSF Biomarkers of Neurodegeneration in Progressive Non-fluent Aphasia and Other Forms of Frontotemporal Dementia: Clues for Pathomechanisms? | Q64891208 | ||
| Results from a pilot study on amiodarone administration in monogenic frontotemporal dementia with granulin mutation | Q87359504 | ||
| Tau-aggregation inhibitor therapy for Alzheimer's disease | Q22252512 | ||
| Classification of primary progressive aphasia and its variants | Q24594803 | ||
| Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia | Q24598142 | ||
| Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines | Q24598853 | ||
| Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics | Q24630362 | ||
| Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS | Q24633692 | ||
| A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD | Q24634583 | ||
| Cognition and anatomy in three variants of primary progressive aphasia | Q24650108 | ||
| Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum | Q24657634 | ||
| Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease | Q26739412 | ||
| Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging | Q27020981 | ||
| Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q28131672 | ||
| Primary progressive aphasia | Q28213380 | ||
| A clinicopathological approach to the diagnosis of dementia | Q39434968 | ||
| Characterizing TDP-43 interaction with its RNA targets | Q40367013 | ||
| Frontotemporal dementia with a C9ORF72 expansion in a Swedish family: clinical and neuropathological characteristics | Q41849494 | ||
| Distinct tau prion strains propagate in cells and mice and define different tauopathies | Q41904960 | ||
| Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. | Q41933726 | ||
| Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. | Q41955482 | ||
| A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment | Q43958437 | ||
| Emerging Diagnostic and Therapeutic Strategies for Tauopathies | Q45870549 | ||
| Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia | Q46047796 | ||
| Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia | Q46080645 | ||
| Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies | Q47947288 | ||
| Psychiatric Presentations of C9orf72 Mutation: What Are the Diagnostic Implications for Clinicians? | Q47960501 | ||
| Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias | Q48010180 | ||
| Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. | Q48384360 | ||
| Frontotemporal dementia: latest evidence and clinical implications | Q49430878 | ||
| Clinicopathological correlations in corticobasal degeneration | Q28245070 | ||
| Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17 | Q28274687 | ||
| The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier) | Q28485924 | ||
| Frontotemporal Dementia | Q30234793 | ||
| Early Noninvasive Diagnosis of Neurodegenerative Diseases | Q30393556 | ||
| The logopenic/phonological variant of primary progressive aphasia | Q30487374 | ||
| Asymmetry of cortical decline in subtypes of primary progressive aphasia | Q30588023 | ||
| Imaging frontotemporal lobar degeneration | Q30846573 | ||
| Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology | Q31155412 | ||
| Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration | Q33610029 | ||
| Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia | Q33859252 | ||
| Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias | Q33864510 | ||
| Determinants of survival in behavioral variant frontotemporal dementia. | Q33898199 | ||
| Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration | Q33999208 | ||
| Distinct pathological subtypes of FTLD-FUS. | Q34024578 | ||
| Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial | Q34031302 | ||
| Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia | Q34079305 | ||
| Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations | Q34134801 | ||
| ALS-Plus syndrome: non-pyramidal features in a large ALS cohort. | Q34257559 | ||
| Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease | Q34282454 | ||
| Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion | Q34399242 | ||
| Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop | Q34733901 | ||
| Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia | Q34749217 | ||
| The clinical profile of right temporal lobe atrophy | Q34964995 | ||
| Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine | Q35204586 | ||
| White matter damage in primary progressive aphasias: a diffusion tensor tractography study. | Q35275364 | ||
| Neuroanatomical correlates of behavioural disorders in dementia | Q35677177 | ||
| Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis | Q35750755 | ||
| Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration | Q35773678 | ||
| Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations | Q35776901 | ||
| Advances in neuroimaging in frontotemporal dementia. | Q36097857 | ||
| Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features | Q36198642 | ||
| Treatment approaches to symptoms associated with frontotemporal degeneration | Q36282272 | ||
| Atypical antipsychotic use in patients with dementia: managing safety concerns | Q36450333 | ||
| Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms | Q36482533 | ||
| Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis | Q36527483 | ||
| Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease | Q36626657 | ||
| The natural history of temporal variant frontotemporal dementia | Q36647734 | ||
| Criteria for the diagnosis of corticobasal degeneration | Q36661843 | ||
| Advances in understanding the molecular basis of frontotemporal dementia | Q36775677 | ||
| Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. | Q36934178 | ||
| Epidemiology of early-onset dementia: a review of the literature | Q37025574 | ||
| Antisense reduction of tau in adult mice protects against seizures | Q37058143 | ||
| Frontotemporal dementia: clinicopathological correlations | Q37069848 | ||
| Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial | Q37131376 | ||
| Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). | Q37138811 | ||
| Spontaneous social behaviors discriminate behavioral dementias from psychiatric disorders and other dementias | Q37327458 | ||
| Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration | Q37340843 | ||
| Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. | Q37349806 | ||
| Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech | Q37356674 | ||
| Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations | Q37368352 | ||
| Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease | Q37381059 | ||
| The heritability and genetics of frontotemporal lobar degeneration. | Q37425094 | ||
| Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. | Q37428437 | ||
| Therapy and clinical trials in frontotemporal dementia: past, present, and future | Q37566888 | ||
| Frontotemporal lobar degeneration: current perspectives | Q37591327 | ||
| Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. | Q37652962 | ||
| Neuropathological background of phenotypical variability in frontotemporal dementia | Q37879961 | ||
| Structure, function, and mechanism of progranulin; the brain and beyond | Q37892442 | ||
| New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. | Q38149943 | ||
| Divergent Longitudinal Propagation of White Matter Degradation in Logopenic and Semantic Variants of Primary Progressive Aphasia | Q38401633 | ||
| Tau immunotherapy for Alzheimer's disease | Q38407801 | ||
| Left/right asymmetry of atrophy in semantic dementia: behavioral-cognitive implications | Q38425469 | ||
| Longitudinal white matter changes in frontotemporal dementia subtypes. | Q38426470 | ||
| Clinical update on frontotemporal dementia: diagnosis and treatment. | Q38439741 | ||
| Motor neuron dysfunction in frontotemporal dementia. | Q38486371 | ||
| Genetics of frontotemporal dementia in Asia: Advancing knowledge through collaboration | Q38598257 | ||
| Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria | Q38807324 | ||
| Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies | Q38866202 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | frontotemporal dementia | Q18592 |
| P577 | publication date | 2019-02-21 | |
| P1433 | published in | Frontiers in Psychiatry | Q27723495 |
| P1476 | title | Precision Medicine for Frontotemporal Dementia | |
| P478 | volume | 10 |
| Q90591149 | Development of disease-modifying drugs for frontotemporal dementia spectrum disorders | cites work | P2860 |
Search more.